Cambridge, Massachusetts (April 20, 2016): PixarBio Corporation inventors of NeuroRelease, a 14-day non-opioid, non-addictive, post-surgical pain treatment with expected FDA approval in 2018, today announced that it has been named one of the “Best Places to Work” by the Boston Business Journal.
PixarBio has been selected as a best place to work, extra small category (20-49 employees), on the annual regional list created by the Boston Business Journal, a cross-industry publication in the Boston area. The Boston Business Journal surveys local companies to determine which firms offer the greatest professional opportunities and work environments.
“We are extremely pleased to recognize these companies that clearly value their employees and go the extra mile to create great workplaces,” said Carolyn M. Jones, the Boston Business Journal Market President and Publisher.
“Our only FDA approved competitor uses a neurotoxic drug in an old lipid based drug delivery system. Silly choices for a nerve block expected to last more than 3 days. Our culture creates safe & effective products for humans. Our people create paths for others to follow. We are valued and respected. Its win-win-win for patients, and all stakeholders in the healthcare system,” said PixarBio CEO Frank Reynolds.
PixarBio…WE GOT THIS!!™
About PixarBio Corporation
Cofounded by Frank M. Reynolds, MIT’s Dr. Robert S. Langer, Katrin Holzhaus, and Dr. Jason Criscione, PixarBio researches and develops targeted delivery systems for drugs, cells, or biologics to treat pain, epilepsy, Parkinson’s disease, and spinal cord injury. For more information visit www.pixarbio.com.